CN102164905B - 作为体内缺氧模拟剂的化合物，组合物，及其应用 - Google Patents

作为体内缺氧模拟剂的化合物，组合物，及其应用 Download PDF

Info

Publication number
CN102164905B
CN102164905B CN201080002367.7A CN201080002367A CN102164905B CN 102164905 B CN102164905 B CN 102164905B CN 201080002367 A CN201080002367 A CN 201080002367A CN 102164905 B CN102164905 B CN 102164905B
Authority
CN
China
Prior art keywords
oxo
chromenyl
carbonyl
glycine
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080002367.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102164905A (zh
Inventor
康心汕
龙伟
马存波
王燕萍
曹红
王印祥
谭芬来
胡云雁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Beta Pharma Inc
Original Assignee
Zhejiang Beta Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc filed Critical Zhejiang Beta Pharma Inc
Priority to CN201080002367.7A priority Critical patent/CN102164905B/zh
Publication of CN102164905A publication Critical patent/CN102164905A/zh
Application granted granted Critical
Publication of CN102164905B publication Critical patent/CN102164905B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080002367.7A 2009-07-15 2010-07-14 作为体内缺氧模拟剂的化合物，组合物，及其应用 Expired - Fee Related CN102164905B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201080002367.7A CN102164905B (zh) 2009-07-15 2010-07-14 作为体内缺氧模拟剂的化合物，组合物，及其应用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200910089274 2009-07-15
CN200910089274.1 2009-07-15
CN201080002367.7A CN102164905B (zh) 2009-07-15 2010-07-14 作为体内缺氧模拟剂的化合物，组合物，及其应用
PCT/CN2010/001057 WO2011006355A1 (en) 2009-07-15 2010-07-14 Compounds as hypoxia mimetics, and compositions, and uses thereof

Publications (2)

Publication Number Publication Date
CN102164905A CN102164905A (zh) 2011-08-24
CN102164905B true CN102164905B (zh) 2014-04-30

Family

ID=43448908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080002367.7A Expired - Fee Related CN102164905B (zh) 2009-07-15 2010-07-14 作为体内缺氧模拟剂的化合物，组合物，及其应用

Country Status (13)

Country Link
US (1) US8742138B2 (enExample)
EP (1) EP2454249B1 (enExample)
JP (1) JP5847710B2 (enExample)
KR (1) KR20120065311A (enExample)
CN (1) CN102164905B (enExample)
AU (1) AU2010273101B2 (enExample)
CA (1) CA2767911C (enExample)
ES (1) ES2702524T3 (enExample)
IL (1) IL217531A0 (enExample)
IN (1) IN2012DN00549A (enExample)
SG (1) SG177598A1 (enExample)
WO (1) WO2011006355A1 (enExample)
ZA (1) ZA201200293B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2606631T3 (es) 2011-07-22 2017-03-24 Beijing Betta Pharmaceuticals Co., Ltd Formas polimeróficas de compuestos como inhibidor de la prolila hidroxilasa, y usos de los mismos
WO2013017063A1 (en) * 2011-07-29 2013-02-07 Zhejiang Beta Pharma Incorporation Stable polymorphic forms of compound as hypoxia mimetics, and uses thereof
EP3190104B1 (en) 2014-09-02 2021-10-27 Sunshine Lake Pharma Co., Ltd. Quinolinone compound and use thereof
WO2016111523A2 (ko) * 2015-01-05 2016-07-14 국립암센터 HNF4-α 길항제 및 이의 용도
CN108367017A (zh) 2015-08-13 2018-08-03 索马根尼科斯公司 用于伤口愈合的短小发夹rna与微rna的组合物以及方法
ES2934361T3 (es) 2017-05-09 2023-02-21 Kind Pharmaceutical Derivados de indolizina y aplicación de los mismos en medicina

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009100250A1 (en) * 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080649A2 (en) 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
AU2006282888A1 (en) * 2005-08-25 2007-03-01 Emory University HIF inhibitors
US7728130B2 (en) 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
US8324235B2 (en) 2007-03-29 2012-12-04 Novartis Ag Heterocyclic spiro-compounds
EP2341904A1 (en) * 2008-08-26 2011-07-13 Fibrogen, Inc. Methods for treatment of multiple sclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
WO2007103905A2 (en) * 2006-03-07 2007-09-13 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
WO2009100250A1 (en) * 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors

Also Published As

Publication number Publication date
KR20120065311A (ko) 2012-06-20
EP2454249A1 (en) 2012-05-23
CA2767911A1 (en) 2011-01-20
EP2454249B1 (en) 2018-09-19
US8742138B2 (en) 2014-06-03
ES2702524T3 (es) 2019-03-01
EP2454249A4 (en) 2012-12-12
CN102164905A (zh) 2011-08-24
US20120172399A1 (en) 2012-07-05
JP2012532897A (ja) 2012-12-20
IN2012DN00549A (enExample) 2015-06-12
AU2010273101B2 (en) 2016-02-25
HK1161234A1 (en) 2012-08-24
JP5847710B2 (ja) 2016-01-27
AU2010273101A1 (en) 2012-02-02
WO2011006355A1 (en) 2011-01-20
AU2010273101A2 (en) 2012-03-15
SG177598A1 (en) 2012-02-28
ZA201200293B (en) 2012-09-26
IL217531A0 (en) 2012-02-29
CA2767911C (en) 2016-03-29

Similar Documents

Publication Publication Date Title
JP6099644B2 (ja) プロリルヒドロキシラーゼ阻害剤としての化合物の多形体、およびその使用
ES2446418T3 (es) Derivados de indanona que inhiben la prolil hidroxilasa
CN102164905B (zh) 作为体内缺氧模拟剂的化合物，组合物，及其应用
CN113173924B (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
KR102636166B1 (ko) GPR120 조절제로서의 테트라하이드로-벤조[d]아제핀 유도체
CN103328430A (zh) 作为s-亚硝基谷胱甘肽还原酶抑制剂的新型取代的双环芳族化合物
CN110041333A (zh) 溴结构域抑制剂化合物及其用途
CN114981263A (zh) 新型槲皮素氧化还原衍生物及作为bet抑制剂的用途
EP2201011A2 (en) Novel compounds having indazole frameworks, methods for preparing the same and pharmaceutical composition comprising the same
CN103641827B (zh) 中氮茚衍生物及其合成方法和应用
JP6855505B2 (ja) ブロモドメイン阻害剤としてのカルボリン誘導体
JP6052673B2 (ja) ピラゾール誘導体またはその塩ならびにそれらを含有する医薬組成物
TWI424842B (zh) 含取代基的雜環化合物、包括其的藥物組合物，以及該化合物的應用
CN111683934A (zh) (r)-3-(1-(2,3-二氯-4-(吡嗪-2-基)苯基)-2,2,2-三氟乙基)-1-甲基-1-(1-甲基哌啶-4-基)脲的延胡索酸盐、制备方法及其用途
HK1161234B (en) Compounds as hypoxia mimetics, and compositions, and uses thereof
CN110684020B (zh) 2-胺基嘧啶类衍生物、其制备方法及其在医药上的应用
WO2025252099A1 (zh) 一种吡咯并六元芳环化合物及其制备方法和应用
CN107162913A (zh) 一类新型氘代苯丙酸衍生物、其制备方法及其作为药物的用途
CN118139837A (zh) 二苯乙烯衍生物及其制备方法和用途
CN110194744A (zh) 一种抑制β-淀粉样蛋白生成的化合物及其制备方法和用途
JP2010195688A (ja) Ｎｐｙｙ５受容体拮抗作用を有するアミド及びウレア誘導体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161234

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1161234

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140430

CF01 Termination of patent right due to non-payment of annual fee